Frontiers in Immunology (Apr 2021)
Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner
- Andreas Linder,
- Andreas Linder,
- Viktoria Bothe,
- Nicolas Linder,
- Paul Schwarzlmueller,
- Frank Dahlström,
- Christoph Bartenhagen,
- Martin Dugas,
- Dharmendra Pandey,
- Julia Thorn-Seshold,
- Julia Thorn-Seshold,
- Daniel F. R. Boehmer,
- Lars M. Koenig,
- Sebastian Kobold,
- Sebastian Kobold,
- Max Schnurr,
- Johannes Raedler,
- Giulia Spielmann,
- Hadi Karimzadeh,
- Hadi Karimzadeh,
- Andreas Schmidt,
- Stefan Endres,
- Stefan Endres,
- Simon Rothenfusser,
- Simon Rothenfusser
Affiliations
- Andreas Linder
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Andreas Linder
- Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
- Viktoria Bothe
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Nicolas Linder
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Paul Schwarzlmueller
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Frank Dahlström
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Christoph Bartenhagen
- Institute of Medical Informatics, University of Münster, Münster, Germany
- Martin Dugas
- Institute of Medical Informatics, University of Münster, Münster, Germany
- Dharmendra Pandey
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Julia Thorn-Seshold
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Julia Thorn-Seshold
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Daniel F. R. Boehmer
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Lars M. Koenig
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Sebastian Kobold
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Sebastian Kobold
- German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
- Max Schnurr
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Johannes Raedler
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Giulia Spielmann
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Hadi Karimzadeh
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Hadi Karimzadeh
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Andreas Schmidt
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Stefan Endres
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Stefan Endres
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Simon Rothenfusser
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
- Simon Rothenfusser
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- DOI
- https://doi.org/10.3389/fimmu.2021.595390
- Journal volume & issue
-
Vol. 12
Abstract
Replication competent vesicular stomatitis virus (VSV) is the basis of a vaccine against Ebola and VSV strains are developed as oncolytic viruses. Both functions depend on the ability of VSV to induce adequate amounts of interferon-α/β. It is therefore important to understand how VSV triggers interferon responses. VSV activates innate immunity via retinoic acid-inducible gene I (RIG-I), a sensor for viral RNA. Our results show that VSV needs to replicate for a robust interferon response. Analysis of RIG-I-associated RNA identified a copy-back defective-interfering (DI) genome and full-length viral genomes as main trigger of RIG-I. VSV stocks depleted of DI genomes lost most of their interferon-stimulating activity. The remaining full-length genome and leader-N-read-through sequences, however, still triggered RIG-I. Awareness for DI genomes as trigger of innate immune responses will help to standardize DI genome content and to purposefully deplete or use DI genomes as natural adjuvants in VSV-based therapeutics.
Keywords
- vesicular stomatitis virus (VSV)
- retinoid acid inducible gene I (RIG-I)
- pattern recognition receptor (PRR)
- pathogen associated molecular pattern (PAMP)
- nucleic acid sensing
- defective interfering genome